Skip to main content
Explore URMC
menu

Leukemia (AML & MDS): Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Research Question:
What are the good and bad effects of using different new treatment options (azacitidine & nivolumab or azacitidine & midostaurin) to one of the current standard treatment options (azacitidine alone) given for patients with AML or MDS who cannot tolerate or do not want to get intensive chemotherapy?

Basic Study Information

Purpose:
If you participate in this study you will randomly be assigned to one of the following treatment groups; Group A: azacitidine alone, Group B: azacitidine and nivolumab, or Group C: azacitidine and midostaurin. The cycles for all study groups will repeat until your disease gets worse or you or your study doctor decide you should stop. Each cycle is 28 days.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03092674?term=S1612&rank=2
Study Reference #: CLEU18002

Lead Researcher (Principal Investigator)

Lead Researcher: Kristen O'Dwyer

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Leukemia, Myeloid, Acute

Return to Search